Study Evaluating IMA-638 in Healthy Japanese - Full Text View

Sponsored by:	Wyeth
Information provided by:	Wyeth
ClinicalTrials.gov Identifier:	NCT00340327

Purpose

The purpose of this study is to evaluate the safety and drug levels for single, ascending doses of IMA-638 in healthy Japanese subjects.

Condition	Intervention	Phase
Healthy	Drug: IMA-638	Phase I

Study Type:	Interventional
Study Design:	Diagnostic, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety Study
Official Title:	An Ascending Single Dose Study of the Safety and Pharmacokinetics of IMA-638 Administered to Healthy Japanese Subjects

Further study details as provided by Wyeth:

Primary Outcome Measures:

Safety will be measured by evaluating physical examinations, vital signs, electrocardiograms (ECGs), and clinical laboratory test results.

Secondary Outcome Measures:

Study Start Date:	June 2006
Study Completion Date:	July 2007

Eligibility

Criteria

Inclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00340327

Locations

United States, California

Glendale, California, United States, 91206

Sponsors and Collaborators

Wyeth

Investigators

Study Director:

Medical Monitor

Wyeth

More Information

Study ID Numbers:	3174K1-101
Study First Received:	June 16, 2006
Last Updated:	December 3, 2007
ClinicalTrials.gov Identifier:	NCT00340327
Health Authority:	United States: Food and Drug Administration

Keywords provided by Wyeth:

healthy subjects

Study placed in the following topic categories:

Healthy

ClinicalTrials.gov processed this record on January 16, 2009